OMNI Health Media is a leading online provider of Daily Health News. OMNI’s Clinical Trials News provides summaries of developments in the prevention, screening, and management of Gastrointestinal Health Conditions as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating new therapies and supportive care strategies in order to better educate patients and their caregivers, ensuring timely access to the best care available.
First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

April 18, 2018

First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

By Anonymous User anonymous_user_10987

CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with pancreatic cancer will continue to enroll patients based on The Data Monitoring Committee first interim analyses and recommendation. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people […]

View full entry

Tags: AM0010, clinical trials, immunotherapy, Interleukin-10, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, pegilodecakin, Precision Cancer Medicine, treatment

View more articles like this
More news and in-depth Pancreatic Cancer information